CTIBIOTECH

  • Home
  • Company
    • Mission
    • Key Points
    • Key Staff
    • Structural Partners
    • Public Engagement
    • Education
    • Recruitment
    • Laboratory
  • Technology
    • Cancer
    • IMODI
    • Adult Stem Cell Technology Platforms
    • In vitro tox & drug testing
    • Dermatocosmetics / Skin
    • Clinical trials development
    • Biobanking
    • Medical Device R&D
    • Strategic R&D Partners
  • Services
    • Products
      • Tissues and cells
      • Cancer cells
    • Contract testing
    • Medical device
    • Consultancy
    • Our Clients
    • IMODI Products
  • Investors / Media
    • Why we are different
    • News
    • Resources
    • Legal
  • 会社案内
    • 設立 主旨
    • 基盤技術
    • 実績
    • 提供するサービス
    • パートナー
    • 体制
    • 資本
    • パブリケーション
    • サポート
  • Contact

Key Points

More than 25 years experience
30CTICTI BIOTECH was founded in 2009 by Professor Colin McGuckin and Dr Nico Forraz, pioneers in the fields of regenerative medicine and cancer and creators of the world’s first artificial liver-like tissue using a unique form of embryonic-like adult stem cells. The core expertise of CTI BIOTECH is in cell manipulation, drug testing, biobanking and preclinical trials development. Cells as diverse as blood, immune, liver, pancreas, bone, cartilage, neural and skin-related are made in our laboratories.
Diverse technology platforms
30CTICTI BIOTECH is a fully licensed human tissue biobank and is developing proprietary in-house technologies using cancer and stem cells, but also has developmental partners in:
  • Medical device development using human cells
  • In vitro toxicology, drug testing and development
  • Cosmetics and skin-drug testing and creation of skin models
  • Provision of cell models for infectious diseases and cancer testing
International profile and partners
30CTICTI BIOTECH has already contributed to FDA registered and CE marked products available now through our partners. International projects in Europe, Asia and the United States have a proven success record.

COMPANY PROFILE

CTIBIOTECH aims to maximize the potential of tissues created by stem cell technologies and biopsies from cancer and skin for human therapeutic benefit

Read More

NEWS

Read about the latest CTIBIOTECH developments *LATEST* October 2016, CTIBIOTECH will be present in Japan for the BIOJAPAN international meeting

Read more here

SEARCH

Copyright © 2023 · CTIBIOTECH - All rights reserved. Log in